

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed to:


PATENT  
Attorney Docket No.: 020054-001130US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On: January 26, 2004

By: 

Nicole M. Wartell



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Peter S. Lu et al.

Application No.: 09/724,553

Filed: November 28, 2000

For: MOLECULAR INTERACTIONS  
IN T-LYMPHOCYTES  
(AMENDED)

Customer No.: 20350

Confirmation No.: 7232

Examiner: Belyavskyi, Michail A.

Art Unit: 1644

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicants wish to make the Examiner aware of the following co-pending patent applications:

1. U.S. Patent App. No. 09/722,069, filed 11/24/2000, Attorney Docket No. 020054-001122US; and

2. U.S. Patent App. No. 09/688,017, filed 10/13/2000, Attorney Docket No. 020054-001110US.

To comply with 37 CFR §1.98(a)(2)(iii), the specifications, claims and drawings for the above applications are enclosed.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 303-571-4321  
SLA:nmb  
60121832 v1





PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 2 of 3

**Complete if Known**

Application Number	09/724,553
Filing Date	November 28, 2000
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1644
Examiner Name	DeCloux, Amy
Attorney Docket Number	020054-001130US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Altin, J. and Sloan, E. "The role of CD45 and CD45-associated molecules in T cell activation" <i>Immunology and Cell Biology</i> , 1997, pp. 430-445, Vol. 75.	
	C2	Barclay, A., et al., "The Leucocyte Antigen Factsbook", Harcourt Braces & Company, page 363, (1997).	
	C3	Cherukuri, A. et al. "Floating the raft hypothesis: lipid rafts play a role in immune cell activation", <i>Immunity</i> , June 2001, pp.657-660, Vol. 14, Cell Press.	
	C4	Doyle, D. A., et al., "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ", <i>Cell</i> , 85(7):1067-76, (1996).	
	C5	Faulkner, G. et al. "A New Z-band Alternatively Spliced PDZ-motif Protein." <i>The Journal of Cell Biology</i> , July 26, 1999; pp. 465-475, Vol. 146, No. 2.	
	C6	Gardioli, D. et al. "Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation", <i>Oncogene</i> , 18(40):5487-5496, (1999).	
	C7	Kiyono, T. et al. "Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein", <i>Proc. Natl. Acad. Sci.</i> , October 1997, pp. 11612-11616, Vol. 94, U.S.A.	
	C8	Nagase, T. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain (Supplement)", <i>DNA Research</i> , 1996, pp. 341-354, Vol. 3, Supplement.	
	C9	Patel, V. et al., "A Molecular Framework for 2-Step T Cell Signaling: Lck Src Homology 3 Mutations Discriminate Distinctly Regulated Lipid Raft Reorganization Events", <i>Journal of Immunology</i> , 166(2):754-64 (2001).	
	C10	Reynaud, C. et al., "The PDZ Protein TIP-1 Interacts with the Rho Effector Rhotekin and Is Involved in Rho Signaling to the Serum Response Element", <i>The Journal of Biological Chemistry</i> , 275(43):33962-33968, (2000).	
	C11	Rousset, R., et al., "The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins" <i>Oncogene</i> , 16(5):643-54, (1998).	
	C12	Suzuki, T., et al., "Tax oncoprotein of HTLV-1 binds to the human homologue of Drosophila discs large tumor suppressor protein, hDLG, and perturbs its function in cell growth control", <i>Oncogene</i> , 18(44):5967-72, (1999).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

60121832 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 3 of 3

**Complete if Known**

Application Number	09/724,553
Filing Date	November 28, 2000
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1644
Examiner Name	DeCloux, Amy
Attorney Docket Number	020054-001130US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C13	Vallenius, T. et al. "CLP-36 PDZ-LIM Protein Associates with Nonmuscle alpha-Actinin-1 and alpha-Actinin-4." The Journal of Biological Chemistry, April 14, 2000; pp. 11100-11105, Vol. 275, No. 15.	
	C14	Wechsler, A. et al. "Brain Spectrin binding to the NMDA receptor is regulated by phosphorylation, calcium and calmodulin." The EMBO Journal, 1998, pp. 3931-3939, Vol. 17, No. 14.	
	C15	Xia, H. et al. "Actinin-associated LIM Protein: Identification of a Domain Interaction between PDZ and Spectrin-like Repeat Motifs", The Journal of Cell Biology, October 1997, pp. 507-515, Vol. 139, No. 2.	

Examiner  
SignatureDate  
Considered

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



*Lu*

1644

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/724,553
		Filing Date	November 28, 2000
		First Named Inventor	Lu, Peter S.
		Art Unit	1644
		Examiner Name	Belyavskiy, Michail A.
Total Number of Pages in This Submission		Attorney Docket Number	020054-001130US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard, copies of thirty-two (32) cited references
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Scott L. Aussenhus Reg. No. 42,271
Signature	<i>Scott Aussenhus</i>
Date	01-26-04

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Nicole M. Wartell		
Signature	<i>Nicole M. Wartell</i>	Date	01/26/04